Highlights
KLSE: SOLUTN (0093)       SOLUTION ENGINEERING HOLDINGS BHD ACE : Technology
Last Price Today's Change   Day's Range   Trading Volume
1.81   +0.13 (7.74%)  1.61 - 1.84  69,196,500
Trade this stock with T+7 trading account. Find out more.

Additional Listing

Hints :
[1] Click the View Entitlement icon table to view the Additional Listing detail page.

Click here to modify the Visible Columns.

Ann. Date Date Type Units Price Total NOSH View
17-Jun-2013 18-Jun-2013 Private Placement 8,400,000 0.235 177,096,000 Additional Listing Detail
16-Aug-2013 19-Aug-2013 Private Placement 8,460,000 0.250 185,556,000 Additional Listing Detail
05-Sep-2014 08-Sep-2014 ESOS 200,000 0.135 185,756,000 Additional Listing Detail
07-Oct-2014 08-Oct-2014 ESOS 1,681,000 0.135 187,437,000 Additional Listing Detail
24-Oct-2014 27-Oct-2014 ESOS 626,000 0.135 188,063,000 Additional Listing Detail
20-Nov-2014 21-Nov-2014 ESOS 65,000 0.135 188,128,000 Additional Listing Detail
27-Nov-2014 28-Nov-2014 ESOS 8,246,000 0.135 196,374,000 Additional Listing Detail
25-May-2015 26-May-2015 ESOS 40,000 0.135 196,414,000 Additional Listing Detail
10-Jun-2015 11-Jun-2015 ESOS 65,000 0.135 196,479,000 Additional Listing Detail
24-Jun-2015 25-Jun-2015 ESOS 74,000 0.135 196,553,000 Additional Listing Detail
14-Jul-2015 15-Jul-2015 ESOS 260,000 0.185 196,813,000 Additional Listing Detail
03-Aug-2015 04-Aug-2015 ESOS 25,000 0.185 196,838,000 Additional Listing Detail
12-Aug-2015 13-Aug-2015 ESOS 45,000 0.185 196,922,000 Additional Listing Detail
09-Sep-2015 10-Sep-2015 ESOS 338,000 0.185 197,307,000 Additional Listing Detail
11-Sep-2015 14-Sep-2015 ESOS 10,000 0.135 199,760,000 Additional Listing Detail
16-Nov-2015 17-Nov-2015 ESOS 25,000 0.185 199,785,000 Additional Listing Detail
16-Dec-2015 17-Dec-2015 ESOS 30,000 0.185 199,815,000 Additional Listing Detail
18-Apr-2016 19-Apr-2016 ESOS 230,000 0.185 200,045,000 Additional Listing Detail
10-Jun-2016 13-Jun-2016 ESOS 65,000 0.185 200,120,000 Additional Listing Detail
21-Jun-2016 23-Jun-2016 ESOS 2,539,000 0.185 202,659,000 Additional Listing Detail
26-Aug-2016 29-Aug-2016 Exercise of Warrants 2,500 0.200 303,990,865 Additional Listing Detail
08-Dec-2016 09-Dec-2016 ESOS 315,000 0.220 304,305,865 Additional Listing Detail
23-Dec-2016 27-Dec-2016 ESOS 30,000 0.220 304,335,865 Additional Listing Detail
25-Jan-2017 26-Jan-2017 ESOS 1,615,000 0.220 305,950,865 Additional Listing Detail
27-Feb-2017 28-Feb-2017 ESOS 155,000 0.220 306,105,865 Additional Listing Detail
17-Mar-2017 20-Mar-2017 ESOS 60,000 0.220 306,165,865 Additional Listing Detail
12-Apr-2017 13-Apr-2017 ESOS 47,500 0.220 306,213,365 Additional Listing Detail
15-May-2017 16-May-2017 ESOS 30,000 0.220 306,243,365 Additional Listing Detail
30-Jun-2017 03-Jul-2017 ESOS 21,000 0.220 306,264,365 Additional Listing Detail
03-Aug-2017 04-Aug-2017 ESOS 42,000 0.220 306,306,365 Additional Listing Detail
16-Aug-2017 17-Aug-2017 Exercise of Warrants 666 0.200 306,307,031 Additional Listing Detail
23-Oct-2017 24-Oct-2017 ESOS 147,500 0.220 306,454,531 Additional Listing Detail
07-Sep-2020 08-Sep-2020 ESOS 170,000 0.220 306,624,531 Additional Listing Detail
10-Sep-2020 11-Sep-2020 ESOS 850,000 0.220 307,474,531 Additional Listing Detail
21-Sep-2020 23-Sep-2020 ESOS 220,000 0.175 307,694,531 Additional Listing Detail
24-Sep-2020 28-Sep-2020 ESOS 65,000 0.175 307,759,531 Additional Listing Detail
30-Sep-2020 02-Oct-2020 ESOS 45,000 0.175 307,804,531 Additional Listing Detail
08-Oct-2020 12-Oct-2020 ESOS 250,000 0.175 308,204,531 Additional Listing Detail
14-Oct-2020 16-Oct-2020 ESOS 35,000 0.175 308,339,531 Additional Listing Detail
22-Oct-2020 23-Oct-2020 ESOS 500,000 0.175 308,839,531 Additional Listing Detail
28-Oct-2020 30-Oct-2020 Exercise of Warrants 1,200,000 0.200 310,039,531 Additional Listing Detail
05-Nov-2020 09-Nov-2020 Exercise of Warrants 49,700 0.200 310,089,231 Additional Listing Detail
10-Nov-2020 12-Nov-2020 Exercise of Warrants 667,307 0.200 310,756,538 Additional Listing Detail
17-Nov-2020 19-Nov-2020 Exercise of Warrants 1,558,000 0.200 312,314,538 Additional Listing Detail
19-Nov-2020 23-Nov-2020 ESOS 216,000 0.175 312,530,538 Additional Listing Detail
20-Nov-2020 23-Nov-2020 Exercise of Warrants 5,719,800 0.200 318,250,338 Additional Listing Detail
25-Nov-2020 26-Nov-2020 Exercise of Warrants 4,861,800 0.200 323,112,138 Additional Listing Detail
27-Nov-2020 30-Nov-2020 ESOS 20,000 0.175 323,132,138 Additional Listing Detail
30-Nov-2020 01-Dec-2020 Exercise of Warrants 2,180,000 0.200 325,312,138 Additional Listing Detail
02-Dec-2020 03-Dec-2020 Exercise of Warrants 2,021,000 0.200 327,333,138 Additional Listing Detail
Analyze this stock with MQ Trader system

  15 people like this.
 
lee9fold CKNG8291 Beware of water falls soon
04/12/2020 11:23 PM

u want to act pro again?
05/12/2020 12:43 AM
NPRA1985 DUBAI: Bahrain said on Friday it has granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, becoming the second country after Britain to approve it.

The kingdom had also approved Sinopharm’s COVID-19 vaccine in November for use by frontline workers.

https://www.arabnews.com/node/1772516/middle-east
05/12/2020 1:29 AM
NPRA1985 South Korea reaches deal to buy AstraZeneca's Covid-19 vaccine candidate

https://www.straitstimes.com/asia/east-asia/south-korea-reaches-deal-to-buy-astrazenecas-covid-19-vaccine-candidate
05/12/2020 1:45 AM
hashimM88 https://malaysia.yahoo.com/news/dr-noor-hisham-malaysia-start-115144228.html
05/12/2020 6:30 AM
hashimM88 Is Medical Biology Chinese Academy of Medical Sciences in Beijing producing cansino vaccine (Solutn company)?
05/12/2020 6:32 AM
Jjkcl Asia
05/12/2020 6:40 AM
DawscpJ why not today saturday is monday haha
05/12/2020 6:48 AM
Victorino This is just the beginning, imagine those people eventually wake up from glove stock (top glove, supermax, kossan, hartalega... All move to here this Vaccine Ace stock will be flood.... We can celebrate Christmas, CNY earlier
Also US closing index ever high on Friday
Monday will be no longer 1 something.. It will be 2 something
Mark my word.
I will give a good opening at 1.88
Cheers
05/12/2020 6:56 AM
Victorino By before end of next week it will be start from RM3..
05/12/2020 6:58 AM
18KHarmoni Who are u to give opening price here n there at yr figure? Talk kok
05/12/2020 9:35 AM
joyvest i queue to buy at 1.88 so opening price at least 1.88. highest bid will get the worm....
05/12/2020 10:19 AM
Victorino We should ban 18k harmoni.. Really no manners.
05/12/2020 11:00 AM
pang72 It is easy to invest in Solution.
Buy and book your lobster dinner everyday..

No need to do anything...
Just celebrate everyday till rm3
05/12/2020 11:09 AM
UlarSawa 1 solution can buy 10 kanger. why no one buy kanger. all buy solution? correct?
05/12/2020 11:17 AM
paktua73 kanger is bamboo wet now..
after vaccines start distributed then his fly


tut tut
be part of paktua team..we can ride more..
05/12/2020 11:25 AM
pang72 Sell your kossan and buy 3 Solution..

Else, one kossan can buy 2 solution next 2 weeks from now!

China hints to announce vaccine widely use in 2 weeks time!!
05/12/2020 11:32 AM
joyvest buy what is worth and not what is cheap or expensive for ular
05/12/2020 11:36 AM
joyvest yeap you got the point ...sell 1 for 3 ..... very tempting ......
05/12/2020 11:38 AM
UlarSawa you mean kanger vaccine is fake. solution vaccine is real? correct?
05/12/2020 12:35 PM
joyvest kanger sounds "danger" to me if you change the letter " K" in front . my advice is always buy what is worth and not what is cheap or expensive........
05/12/2020 12:58 PM
UlarSawa you mean solution worth the money at rm1.80? How you prove it? How you work out the profit can be generated from vaccine? 1 dose earn rm ? x hiw many dose? correct?
05/12/2020 1:04 PM
UlarSawa what if gorvernment fix the selling price for the vaccine. can solution earn that much to justify the current price? anyone ever calculate this earning? correct?
05/12/2020 1:10 PM
NPRA1985 500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/
05/12/2020 2:31 PM
joyvest Solu is the authorised distributor agent with exclusive right.fixing price or not is not an issue.profit is there.by the time you find out how much they earn ,its share price would be higher than 1.80....u will keep asking why....

It is now or never.current price is still worth to buy ....dont be an ular be a bull....
05/12/2020 2:32 PM
NPRA1985 https://www.nst.com.my/news/nation/2020/12/646768/malaysias-first-covid-19-vaccine-trial-involve-3000-people
05/12/2020 2:32 PM
joyvest Later when it goes up 2 and higher and higher ..dont ask me how they do that....
05/12/2020 2:34 PM
mf Coronavirus: China to have 600 million doses of vaccines ‘ready for use this year’
By ZHUANG PINGHUI
CHINA
Saturday, 05 Dec 202010:47 AM MYT
05/12/2020 3:24 PM
UlarSawa you mean everyone chase high then it become bull. just like glove ctrs. Topglove all chase until rm30. after split into 3. now hardly can go back to rm20 equivalent. will solution be like this?
05/12/2020 4:06 PM
007007 One thing you can be sure is that there will be plenty of positive vaccine news coming out from all over the world over the coming weeks and months that will be positive for share prices of companies involved in vaccines collaborations, distribution,logistics, etc ......next year will be a year of covid vaccines as world emergency and humanitarian efforts take place.
05/12/2020 4:44 PM
Biliskecil You doubt you wait = you lose
05/12/2020 5:02 PM
Biliskecil Same like those who doubt glove in March 2020
05/12/2020 5:05 PM
lavenderguy Any support group/telegram group?thanks all
05/12/2020 5:10 PM
joyvest Nevermind.u keep asking and we keep making....u look but don't see snd u hear but not listen. your being stuck-up is the obstacle of your own progress...
05/12/2020 5:26 PM
Stockisnotfun Huat ar haha
05/12/2020 7:58 PM
DawscpJ if solution hit rm30, here everyone becomes billionair.
05/12/2020 8:37 PM
Redjj1994 can hit rm30 or not we dunno
but no more RM2 after next week!
anyway i aldy collect many during few months ago so let see how it goes!
so sad for those missboaters that still sour grapes here n wan collect cheap price!
05/12/2020 8:43 PM
joyvest If I were them ,I would take immediate action rather than feeling bad at missing the train....its not too late yet.....the train is still awaiting you to go on board before it speeds fast and furious .....
05/12/2020 9:01 PM
vanness_lyh I'm waiting this counter to limit down lol
05/12/2020 9:10 PM
vanness_lyh Priest who volunteered for COVID-19 Moderna vaccine trial passes away !!!


https://aleteia.org/2020/12/01/priest-who-volunteered-for-covid-19-vaccine-trial-passes-away/
05/12/2020 9:12 PM
vanness_lyh A loss PE company with share price up more than 1560%, what comes up will come down eventually hehe ;)
05/12/2020 9:18 PM
pang72 2020 is year of glove
2021 is year of vaccine..

As simple as that!!
05/12/2020 9:19 PM
joyvest Moderna is not associated to this counter
.as such, it doesn't have any negative impact on this counter but it even further endorses the efficacy of the vaccine associated to this counter as there is no report of any side effect and death.....
05/12/2020 9:21 PM
joyvest Market is forward looking and not living under the shadow of the past..share price is reflected at the future prospects ..

another fellow who just looks but can't see.......pathetic
05/12/2020 9:28 PM
vanness_lyh Fibo 50 around 0.965, hold tight tight ya
Good luck guys ;)
05/12/2020 9:30 PM
NPRA1985 How China’s COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca

But amid the optimism, experts have raised some concerns about the accessibility of Pfizer and Moderna's candidates, which require costly cold-chain distribution mechanisms, and about the quality of the data provided by British vaccine maker AstraZeneca.

At the same time, China's two leading vaccine makers—the private Sinovac and state-owned Sinopharm—appear close to rolling out their vaccines in coming weeks with candidates that don't require expensive cold chain networks.

Western vaccine makers appear to have taken the lead in the global race to produce a vaccine, but Chinese vaccine makers may help fill in the gaps they leave behind.

Still, Pfizer and Moderna’s vaccines are based on newly-developed mRNA technology that requires the candidates to be kept at sub-zero temperatures during shipments. Such temperature restrictions will make it difficult for lower- and middle-income countries to access the vaccines because they will need cold-storage infrastructure to distribute the doses.

In Indonesia, for example, the country's state-owned vaccine manufacturer Bio Farma said that Indonesia, the world's fourth-most populous nation, effectively cannot purchase Pfizer's vaccine given the logistical challenges in distributing it.

"Indonesia does not have such [cold-chain] capabilities, and it is hazardous if this vaccine is not stored at the proper temperature," Honesti Basyir, head Bio Farma, told Indonesian news outlet the Jakarta Globe on Nov. 22. In India, the country's 28,000-unit cold chain network used for distributing vaccines only handles vaccines between 2 and 8 degrees Celsius.

But in the days after AstraZeneca’s announcement, experts raised questions over the "transparency and rigor" of AstraZeneca’s data. Scientists questioned why the most effective results emerged from an apparent dosing error, and how datasets from multiple countries were combined and tabulated into the final results. In response, a spokesperson for AstraZeneca said its trials were conducted to the "highest standards." Still, amid the questions over its trial data, AstraZeneca CEO Pascal Soriot pledged that the company would conduct an additional study to validate its results

AstraZeneca’s woes and the potential distribution limitations of the Pfizer and Moderna vaccines have left a hole in the global supply that may be filled by Chinese vaccine makers, says Yanzhong Huang, senior fellow for global health at the Council on Foreign Relations.

Sinovac and Sinopharm, China’s two leading vaccine makers, are currently testing three vaccine candidates in phase III trials with candidates that could be distributed without cold storage chains. Sinovac's candidate, called CoronaVac, uses inactivated forms of COVID-19 to induce immune responses. Sinopharm's two unnamed candidates are both based on similar technology.

Beijing "absolutely" sees these Chinese-made vaccines as a potential substitution for AstraZeneca's candidate, says Huang. In state media outlets, Beijing is presenting Sinovac and Sinopharm's candidates as "particularly attractive to lower and middle income countries, especially the ones who cannot afford or don't have the capacity to sustain cold chain to distribute vaccines," Huang says.

Because they rely on inactivated forms of the virus, Sinovac's and Sinopharm's candidates are more stable in comparison to vaccines based on mRNA technology, meaning they don't need to be kept quite as cold. Similar to AstraZeneca, Sinovac says its vaccine can be stored and shipped at temperatures ranging from 2 to 8 degrees Celsius. Chinese state media reports that Sinopharm's candidates can likely be stored at a similar 2 to 8 degree Celsius range. Sinopharm declined Fortune's request for confirmation.

Admiral Craig Fuller, the U.S.'s top commander in Central and South America, told reporters this week that while the U.S. is focused "on taking care of the U.S. first," China is poised to deploy its vaccines around the world.

Still, Sinopharm may have a built-in edge given its established distribution networks within China and the fact that it is testing its vaccine in a broader array of countries than other Chinese vaccine makers.

"[Sinopharm's] large scale rollout [via China's emergency use program] also means that there is already a large distribution system, which has already been stress-tested," says Nicholas Thomas, a vaccine expert and health governance professor at the City University of Hong Kong. "This is a major advantage in the future distribution." Sinopharm is also already distributing vaccines to the United Arab Emirates via that country's emergency use program, and is testing, or plans to conduct trials, in at least ten countries including Egypt, Jordan, and Argentina.
05/12/2020 10:14 PM
NPRA1985 https://fortune.com/2020/12/05/china-covid-19-vaccines-approval-sinovac-sinopharm/
05/12/2020 10:15 PM
daijiao collect more while still cheap. Solutions is the only vaccine distributor in Malaysia whose already started to build the facilities n logistic, they look into this business seriously. Unlike others, only press release, blow the wind. end up, goreng goreng n cabut...
05/12/2020 10:26 PM
lee9fold vanness_lyh Fibo 50 around 0.965, hold tight tight ya
Good luck guys ;)
05/12/2020 9:30 PM

another 1 to act pro?
06/12/2020 2:31 AM
NPRA1985 EU criticises ‘hasty’ UK approval of COVID-19 vaccine
European Medicines Agency says its approval process is more appropriate, as German politician calls UK move ‘problematic’.

European regulators have issued caution over the United Kingdom’s move to approve Pfizer-BioNTech’s COVID-19 vaccine for widespread use, saying their longer approval process was safer.

In an unusually blunt statement, the European Medicines Agency (EMA), which is in charge of approving COVID-19 vaccines for the EU, said its longer approval procedure was more appropriate as it was based on more evidence and required more checks than the emergency procedure chosen by the UK.

A spokesman for the European Commission, the EU executive, said the EMA’s procedure was “the most effective regulatory mechanism to grant all EU citizens’ access to a safe and effective vaccine,” as it was based on more evidence.

The EMA’s comments came hours after the UK became the first country in the world to approve the drug developed by Pfizer and BioNTech for use.

Peter Liese, an EU legislator and member of German Chancellor Angela Merkel’s Christian Democratic Union party, struck a firmer tone, saying he considered the MHRA’s approval to be “problematic”.

“I recommend that EU member states do not repeat the process in the same way,” he said.

“A few weeks of thorough examination by the European Medicines Agency (EMA) is better than a hasty emergency marketing authorisation of a vaccine.”

https://www.aljazeera.com/news/2020/12/2/eu-criticises-hasty-uk-approval-of-covid-19-vaccine
06/12/2020 2:33 AM
NPRA1985 Pfizer shares fall on report company cut its Covid vaccine rollout target

Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.

The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021.

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.

https://www.cnbc.com/2020/12/03/pfizer-shares-fall-on-report-company-cut-its-covid-vaccine-rollout-target.html
-----------------------------

Pfizer Scaled Back 2020 COVID-19 Vaccine Production Targets From 100 Million to 50 Million Doses

Pfizer scaled back its Covid-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.

In news releases through September, Pfizer had said that it aimed to manufacture up to 100 million vaccine doses this year. But in several releases in November, the company cut that to an estimate of up to 50 million doses. Pfizer is developing its vaccine with Germany-based BioNTech SE.

A Pfizer spokeswoman said in a statement Thursday that multiple factors slowed the company down, including the time it took to source large quantities of the raw materials needed to produce the shots. But the company said it has finished bringing its manufacturing up to scale and it is now producing vaccines at a rapid pace.

https://time.com/5917847/pfizer-cut-covid-19-vaccine-targets/
06/12/2020 2:52 AM


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
View Trading Signals and run Live Backtest
MQ Affiliate
Earn rewards with MQ Affiliate Program
 
 

546  656  538  392 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 YONGTAI 0.365+0.07 
 MTRONIC 0.135+0.015 
 HWGB 0.88+0.035 
 SAPNRG 0.125+0.005 
 AT 0.195+0.01 
 MTRONIC-WA 0.09+0.015 
 KNM 0.23+0.02 
 PHB 0.030.00 
 INIX 0.33+0.065 
 EAH 0.03-0.005 

FEATURED POSTS

1. The Equity Market Index Benchmark in Malaysia CMS
2. Trading Scenarios of Derivatives Bursa Derivatives Education Series
3. Derivatives 101 Bursa Derivatives Education Series
4. Why Trade FKLI? Bursa Derivatives Education Series
5. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!
PARTNERS & BROKERS